NBI-34041 is potent and high-affinity CRF1 receptor antagonist. NBI-34041 is safety and efficacy in attenuating elevated stress response. NBI-34041 is effective in reducing endocrine responses to pharmacological and behaviorally bioavailable challenge mediated by CRF(1) receptors. NBI-34041 is safe and does not impair basal regulation of the HPA system but improves resistance against psychosocial stress. NBI-34041 displays that inhibition of the CRF system is a promising target for drug development against depression and anxiety disorders. References: Steckler T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead? Curr Top Behav Neurosci. 2010;2:415-28. Review. PubMed PMID: 21309119.

纯度：≥98%

CAS：268545-87-5